Tomato-made edible COVID-19 vaccine TOMAVAC induces neutralizing IgGs in the blood sera of mice and humans
Zabardast T. Buriev, Shukhrat E. Shermatov, Dilshod E. Usmanov, Mukhammadjon K. Mirzakhmedov, Khurshida A. Ubaydullaeva, Venera Kamburova, B K Rakhmanov, Mirzakamol S. Ayubov, Adkham N. Abdullaev, Jakhongir B. Eshmurzaev, Behzod O. Mamajonov, Akmal A. Tulanov, A. A. Ismailova, Т. А. Петрова, Ramazan J. Rozumbetov, Tamara Aripova, Muzaffar Muminov, Khusnora Ermatova, Dilbar Dalimova, Shahlo U. Turdikulova, Abdusattor Abdukarimov, Ibrokhim Y. Abdurakhmonov
Abstract
Plant-based edible vaccines that provide two-layered protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outweigh the currently used parenteral types of vaccines, which predominantly cause a systemic immune response. Here, we engineered and selected a transgenic tomato genotype (TOMAVAC) that stably synthesized an antigenic S1 protein of SARS-CoV-2. Two-course spaced force-feeding of mice with ≈5.4 μg/ml TOMAVAC increased up to 16-fold the synthesis of RBD-specific NAbs in blood serum and the significant induction of S-IgA in intestinal lavage fluid. In a surrogate virus neutralization test, TOMAVAC-induced NAbs had 15-25% viral neutralizing activity. The results suggested early evidence of the immunogenicity and protectivity of TOMAVAC against the coronavirus disease 2019 (COVID-19) infection. Furthermore, we observed a positive trend of statistically significant 1.2-fold (average of +42.28 BAU/ml) weekly increase in NAbs in the volunteers' serum relative to the initial day. No severe side effects were observed, preliminarily supporting the safety of TOMAVAC. With the completion of future large-scale studies, higher-generation TOMAVAC should be a cost-effective, ecologically friendly, and widely applicable novel-generation COVID-19 vaccine, providing two-layered protection against SARS-CoV-2.